Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2004 Sep 27;15(2):308–319. doi: 10.1016/0272-0590(90)90057-Q

Effect of inhaled azodicarbonamide on F344N rats and B6C3F1 mice with 2-week and 13-week inhalation exposures☆

MA Medinsky ∗, WE Bechtold †, LS Birnbaum ‡, JA Bond ∗, DG Burt †, YS Cheng †, NA Gillett †, DK Gulati §, CH Hobbs †, JA Pickrell †
PMCID: PMC7127326  PMID: 2227158

Abstract

Azodicarbonamide (ADA), a compound used in the baking and plastics industries, has been reported to cause pulmonary sensitization and dermatitis in people. Two-week repeated and 13-week subchronic inhalation exposures of F344N rats and B6C3F1 mice to ADA were conducted to determine the toxicity of inhaled ADA. The mean air concentrations of ADA in the 2-week studies were 207, 102, 52, 9.4, or 2.0 mg/m3. No exposure-related mortality nor abnormal clinical signs were observed in rats or mice during or after exposure. The terminal body weights were slightly depressed in the highest exposure group. Liver weights were lower in male rats exposed to 200 mg ADA/m3. No significant lesions were noted on either gross or histologic evaluation of rats or mice. In the 13-week subchronic study, the mean air concentrations of ADA were 204, 100, or 50 mg/m3. No mortality or clinical signs related to exposure were observed. The terminal body weights of exposed rats were not significantly different from those of control rats but were significantly depressed in mice exposed to 100 or 200 mg ADA/m3. No histopathological lesions were noted in mice. Lung weights were increased and enlarged mediastinal and/or tracheobronchial lymph nodes were noted in rats exposed to 50 mg ADA/m3. No exposure-related lesions were observed microscopically in rats exposed to 100 or 200 mg ADA/m3. All rats in the 50 mg DNA/m3 exposure group only had lung lesions that consisted of perivascular cuffing with lymphocytes and a multifocal type II cell hyperplasia, suggesting a possible immune reaction to an antigen in the lung. Viral titers for rats exposed to 50 mg ADA/m3 were negative for Sendai virus and pneumonia virus of mice, which produce similar lesions. The possibility of an unknown viral antigen causing this lesion cannot be eliminated. Lung tissue from male rats was analyzed for ADA and biurea, the major metabolite of ADA. No ADA was detected. The amount of biurea in the lungs increased nonlinearly with increasing exposure concentration, suggesting that clearance was somewhat impaired with repeated exposures. However, even at the highest exposure concentration, this amount of biurea was less than 1% of the estimated total ADA deposited over the exposure period. In summary, ADA is rapidly cleared from the lungs, even when inhaled at concentrations up to 200 mg/m3. Exposure to ADA for up to 13 weeks did not appear to be toxic to rodents.

Footnotes

☆

The U.S. Government's right to retain a nonexclusive royalty-free license in and to the copyringht covering this paper, for governmental purposes, is acknowledged.

References

  1. Bechtold W.E., Shopp G.M., Cheng Y.S. The determination of biurea in the presence of azodicarbonamide by HPLC. J. Anal. Toxicol. 1988;12:89–93. doi: 10.1093/jat/12.2.89. [DOI] [PubMed] [Google Scholar]
  2. Bechtold W.E., Medinsky M.A., Hobbs C.H. Azodicarbonamide: Methods for the analysis in tissues of rats and inhalation disposition. Xenobiotica. 1989;19:1003–1012. doi: 10.3109/00498258909043157. [DOI] [PubMed] [Google Scholar]
  3. Bonsall J.L. Allergic contact dermatitis to azodicarbonamide. Contact Dermatitis. 1984;10:42. doi: 10.1111/j.1600-0536.1984.tb00060.x. [DOI] [PubMed] [Google Scholar]
  4. Cheng Y.S., Marshall T.C., Henderson R.F., Newton G.J. Use of a jet mill for dispersing dry power for inhalation studies. Amer. Ind. Hyg. Assoc. J. 1985;46:449–454. doi: 10.1080/15298668591395148. [DOI] [PubMed] [Google Scholar]
  5. Cheng Y.S., Barr E.B., Benson J.M., Damon E.G., Medinsky M.A., Hobbs C.H., Goehl T.J. Evaluation of a real-time aerosol monitor (RAM-S) for inhalation studies. Fundam. Appl. Toxicol. 1988;10:321–328. doi: 10.1016/0272-0590(88)90317-x. [DOI] [PubMed] [Google Scholar]
  6. Ellman G.L., Courtner K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetyl cholinesterase activity. Biochem. Pharmacol. 1961;7:88–95. doi: 10.1016/0006-2952(61)90145-9. [DOI] [PubMed] [Google Scholar]
  7. Evelyn K.A., Malloy H.T. Microdetermination of oxyhemoglobin, methemoglobin, and sulfhemoglobin in a single sample of blood. J. Biol. Chem. 1938;126:655–662. [Google Scholar]
  8. Ferris B.G., Jr., Peters J.M., Burgess W.A., Cherry R.B. Apparent effect of an azodicarbonamide on the lungs. J. Occup. Med. 1977;19:424–426. doi: 10.1097/00043764-197706000-00012. [DOI] [PubMed] [Google Scholar]
  9. Gafford F.H., Sharry P.M., Pittman J.A. Effect of azodicarbonamide (1,1′-azobisformamide) on thyroid function. J. Clin. Endocrinol. 1971;32:659–662. doi: 10.1210/jcem-32-5-659. [DOI] [PubMed] [Google Scholar]
  10. Gerlach R.F., Medinsky M.A., Hobbs C.H., Bice D.E., Bechtold W.E., Cheng Y.S., Gillett N.A., Birnbaum L.S., Mauderly J.L. Effect of four-week repeated inhalation exposure to azodicarbonamide on specific and nonspecific airway sensitivity of the guinea pig. J. Appl. Toxicol. 1989;9:145–153. doi: 10.1002/jat.2550090303. [DOI] [PubMed] [Google Scholar]
  11. Hamm T.E. Jr., editor. Complications of Viral and Mycoplasmal Infections in Rodents to Toxicology Research and Testing. Hemisphere; Washington, DC: 1986. [Google Scholar]
  12. Herweh J.E., Fantazier R.M. 1,1′-Azobisformamide. II. Thermal decomposition. Kinetics, products, and decomposition mechanism. J. Org. Chem. 1974;39:786–793. [Google Scholar]
  13. Jones T.C., Mohr U.K., Hunt R.D., editors. Respiratory System. Springer-Verlag; New York: 1985. [Google Scholar]
  14. Medinsky M.A., Chico D.M., Hahn F.F. Correlation of urinary enzyme activity and renal lesions after injection of nickel chloride. In: Nieboer E., Aitio A., editors. Nickel and Human Health: Current Perspectives. Wiley; New York: 1989. in press. [Google Scholar]
  15. Mel'nikova E.A., Selikhova L.N. Blood and liver cholinesterase in poisoning with porophor-505 and celogen. Farmakol. Toksikol. 1965;28:742–744. [PubMed] [Google Scholar]
  16. Mewhinney J.A., Ayres P.H., Bechtold W.E., Dutcher J.S., Cheng Y.S., Bond J.A., Medinsky M.A., Henderson R.F., Birnbaum L.S. The fate of inhaled azodicarbonamide in rats. Fundam. Appl. Toxicol. 1987;8:372–381. doi: 10.1016/0272-0590(87)90086-8. [DOI] [PubMed] [Google Scholar]
  17. Newton G.J., Raabe O.G., Mokler B.W. Cascade impactor design and performance. J. Aerosol Sci. 1977;3:339–347. [Google Scholar]
  18. Oser B.L., oser M., Morgareidge K. Studies of the safety of azodicarbonamide as a flourmaturing agent. Toxicol. Appl. Pharmacol. 1965;7:445–472. doi: 10.1016/0041-008x(65)90146-8. [DOI] [PubMed] [Google Scholar]
  19. Raabe O.G., Al-Bayati M.A., Teague S.V., Rasolt A. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann. Occup. Hyg. 1988;32:53–63. [Google Scholar]
  20. Shopp G.M., Cheng Y.S., Gillett N.A., Bechtold W.E., Medinsky M.A., Hobbs C.H., Birnbaum L.S., Mauderly J.L. Acute inhalation exposure of azodicarbonamide in the guinea pig. Amer. Ind. Hyg. Assoc. J. 1987;48(2):127–132. doi: 10.1080/15298668791384517. [DOI] [PubMed] [Google Scholar]
  21. Slovak A.J.M. Occupational asthmas caused by a plastic blowing agent, azodicarbonamide. Thorax. 1981;36:906–909. doi: 10.1136/thx.36.12.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stadler J.C., Karol M.H. Use of doseresponse data to compare the skin sensitizing abilities of dicyclohexylmethane-4-4′-diisocyanate and picryl chloride in two animal species. Toxicol. Appl. Pharmacol. 1985;78:445–450. doi: 10.1016/0041-008x(85)90251-0. [DOI] [PubMed] [Google Scholar]
  23. Tietz N.W. Saunders; Philadelphia: 1986. pp. 1116–1137. (Textbook of Clinical Chemistry). [Google Scholar]
  24. Whitehead L.W., Robins T.G., Fine L.J., Hansen P.J. Respiratory symptoms associated with the use of azodicarbonamide foaming agent in a plastics injection molding facility. Amer. J. Ind. Med. 1987;11:83–92. doi: 10.1002/ajim.4700110109. [DOI] [PubMed] [Google Scholar]

Articles from Fundamental and Applied Toxicology are provided here courtesy of Elsevier

RESOURCES